US Biotechnology: The Biotech Brief: Week of July 17, 2026

Research evidence excerpt

US Biotechnology: The Biotech Brief: Week of July 17, 2026

omic repeats

astrocytic lipid dysregulation is an early driver of AD (Kim and Halliday, Nat Rev Neurol),

though new melanoma data suggest current genetic testing may miss a meaningful ESC: European Society of Cardiology

proportion of at-risk individuals (Kim et al, JAMA Dermatol). Could CRISPR become a cancer HPV: human papillomavirus

assassin? Researchers engineered Cas12a2 to selectively eliminate HPV-positive and IAS: International AIDS Society

KRAS G12C-mutant cancer cells based on their RNA expression profile (Scholz et al, IP: intellectual property

Nature). For additional research you may have missed, see “Recent Research”. KCRS: Kidney Cancer Research Summit

They did what!? KRAS: Kristen rat sarcoma (common cancer

While you’ve been eyeing the weekend, let’s rewind to what may have flown under the mutation)

radar. We published our updated July catalyst tracker (see our July catalyst tracker). LBA: late-breaking abstract

Ahead of Biogen’s AAIC, we surveyed prescribers and previewed CELIA (see our AD nHCM: non-obstructive hypertrophic

survey and our CELIA preview), though the topline disappointed (see our BIIB080 takes cardiomyopathy

and our 7 additional BIIB080 thoughts). FDA approved Biogen’s Leqembi SC initiation NMIBC: non-muscle invasive bladder cancer

formula 6-weeks ahead of its PDUFA (see our SC approval takes). Meanwhile, Insmed

released 12-month phase 2 TPIP PAH OLE data (see our OLE takes). Elsewhere, the OLE: open label extension

failure of the AZN/ IONS phase 3 CARDIO-TTRansform further highlighted Attruby’s PAH: pulmonary arterial hypertension

potential (see our CARDIO-TTRansform takes). Madrigal also added 3 new patents PDUFA: prescription drug user fee act